What was reported
Six protein-based aging clocks were applied to samples from a rentosertib trial in idiopathic pulmonary fibrosis. The analysis reported shifts toward younger predicted ages in treated groups. This is a new 2026 analysis of an earlier clinical trial, not a newly completed general-aging trial.
What the study measured
Proteomic aging-clock estimates in previously collected clinical samples.
Sample and setting
Secondary analysis of a previous 12-week phase 2a lung-disease trial.
What this does not establish
Changes associated with improvement of lung disease could not be cleanly separated from an aging-specific effect. Agreement among clocks does not establish whole-person rejuvenation.
The next question
Does the result persist after accounting for disease activity and validate against an independent functional endpoint?
This is Karam’s proposed follow-up question, not a claim that the original authors or Karam have already resolved it.
The source record
Alex Zhavoronkov, Fedor Galkin, et al.
Nature Biotechnology · 2026-09-07
Publisher abstract and selected main-text sections checked; no independent reanalysis.